This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Rosuvastatin (Crestor®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1311. 2011
Rosuvastatin (Crestor®) is not recommended for use within NHS Wales for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
The clinical and cost effectiveness evidence provided was not sufficient for AWMSG to recommend its use.
Subject indexing assigned by CRD
Cardiovascular Diseases; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitorss; Pyrimidines; Sulfonamides
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published